|
 To commemorate the 25th year of the listing of Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.) on the National Stock Exchange of India (NSE), a bell ringing ceremony was organized at BKC, Mumbai on 2nd May 2025. On this occasion senior management of Zydus Lifesciences including Pankaj R. Patel, chairman, Dr. Sharvil Patel, managing director, Ganesh Nayak, executive director, and Nitin Parekh, CFO and other senior executives were present. The dignitaries from the Ashish Kumar Chauhan, MD and CEO, NSE and Sriram Krishnan, chief business development officer graced the ceremony.
Over the last 24 years, the company's sales has grown from Rs. 478 crore to Rs. 19,022 crore, a CAGR of 17%, operating profit has grown from Rs. 70 crore to Rs. 5,384 crore a CAGR of 20%, and profits after tax has grown from Rs. 38 crore to Rs. 3,860 crore at CAGR of 21% (in the period from March 31, 2000 to March 31, 2024).
An investor who invested Rs. 1 lakh in the IPO of the company has gone up to Rs. 60 lakhs (including dividends and buybacks) as on 30th April 2025, which is almost 60 times the investment and translates into CAGR of 19%, thereby creating significant shareholder value.
Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited), a leading Indian Pharmaceutical company is a fully integrated, global healthcare provider. With in-depth domain expertise in the field of healthcare, it has strong capabilities across the spectrum of the pharmaceutical value chain.
|